Lactofiltrum® 325 mg + 120 mg
Laktofiltrum® is a unique* 2-in-1 combination of 'sorbent + prebiotic'.
Description
Laktofiltrum®. For gut and skin health!
Hydrolyzed lignin is a natural enterosorbent composed of wood hydrolysis products. It possesses high sorption activity and has a nonspecific detoxifying effect. It binds and removes from the intestines pathogenic bacteria, bacterial toxins, drugs, heavy metal salts, alcohol, allergens, as well as an excess of certain metabolic products.
Lactulose is a synthetic disaccharide, the molecule of which consists of galactose and fructose residues. The lactulose released from the tablets in the large intestine is fermented by the normal gut flora as a substrate, stimulating the growth of bifidobacteria and lactobacilli.
Laktofiltrum® is trusted by millions of consumers: the brand is a winner of the annual voting within the "BRAND No. 1 IN RUSSIA®" award.
Dosage Form and Composition
Tablets.
Number of tablets per package: 30 or 60.
Composition (per tablet): Hydrolyzed Lignin (calculated on a dry substance basis) 355 mg, Lactulose (calculated on a 100% substance basis) 120 mg.
Indications for Use
Imbalances of gut microflora (intestinal dysbiosis), including those resulting from antibiotic therapy; as part of combination therapy for irritable bowel syndrome, hepatitis, and liver cirrhosis; allergic diseases (atopic dermatitis, urticaria); bacterial vaginosis (vaginal dysbiosis).
Dosage and Administration
Orally, if necessary after crushing the tablets, with water, one hour before meals and intake of other medications.
For intestinal dysbiosis:
- Adults and children over 12 years: 2-3 tablets, 3 times a day,
- Children from 8 to 12 years: 1-2 tablets, 3 times a day,
- Children from 3 to 7 years: 1 tablet, 3 times a day,
- Children from 1 to 3 years: ½ tablet, 3 times a day.
For bacterial vaginosis (vaginal dysbiosis):
2 tablets, 3 times a day.
The average duration of treatment is 2-3 weeks.
Pharmacy Supply Terms
Over-the-counter
** According to the results of the 2018 nationwide vote, "Laktofiltrum" is the winner of the annual People's Brand consumer trust award in the "Sorbent Preparation" category. According to IQVIA Solutions LLC, the sales volume of Laktofiltrum in packages for the period January-December 2019 amounted to 2,658 thousand packages.
See also:
Our certificates:
Instructions for Medical Use of Lactofiltrum® 355 mg + 120 mg
Trade Name of the Drug: Lactofiltrum®
International Nonproprietary Name or Chemical (Grouping) Name: Lactulose + Hydrolyzed Lignin
Dosage Form: Tablets
Composition per tablet
Hydrolyzed lignin (calculated on a dry substance basis) 355 mg, Lactulose (calculated on a 100% substance basis) 120 mg
Excipients: Croscarmellose sodium 20mg, Magnesium stearate 5mg, Microcrystalline cellulose up to a tablet weight of 550 mg
Description:
Capsule-shaped, biconvex, dark brown tablets with white-grey specks and a score line.
Pharmacotherapeutic Group: Intestinal adsorbent
ATC Code: A07BC
Pharmacological Properties:
The pharmacological action of the drug is determined by the properties of its active components - lignin and lactulose.
Hydrolyzed lignin is a natural enterosorbent, consisting of wood hydrolysis products. It possesses high sorption capacity and nonspecific detoxifying action. It binds in the intestines and removes from the body pathogenic bacteria and bacterial toxins, drugs, heavy metal salts, alcohol, allergens, as well as an excess of certain metabolic products, including bilirubin, cholesterol, histamine, serotonin, urea, and other metabolites responsible for the development of endogenous toxemia.
It is non-toxic, not absorbed, and is completely eliminated from the intestine within 24 hours.
Lactulose is a synthetic disaccharide, the molecule of which consists of galactose and fructose residues. Lactulose is not absorbed and not hydrolyzed in the stomach and upper intestines. The lactulose released from the tablets in the large intestine is fermented by the normal intestinal flora as a substrate, stimulating the growth of bifidobacteria and lactobacilli. The hydrolysis of lactulose in the large intestine produces organic acids - lactic, acetic, and formic acids, which suppress the growth of pathogenic microorganisms and thereby reduce the production of nitrogen-containing toxic substances. This process leads to an increase in osmotic pressure in the lumen of the large intestine and stimulates peristalsis.
The combined action of the drug is aimed at normalizing the microbiocenosis of the large intestine and reducing the intensity of endogenous toxic conditions.
The use of the drug in the complex therapy of bacterial vaginosis (vaginal dysbiosis) increases treatment efficacy, including by increasing the number of lactobacilli in the vagina and effectively suppressing the growth of opportunistic flora.
Indications for Use:
Imbalances of intestinal microflora (intestinal dysbiosis), including those resulting from antibiotic therapy; as part of combination therapy for irritable bowel syndrome, hepatitis, and liver cirrhosis; allergic diseases (atopic dermatitis, urticaria); bacterial vaginosis (vaginal dysbiosis).
Contraindications
Hypersensitivity to the drug, intestinal obstruction, gastrointestinal bleeding, galactosemia. Use of the drug is not recommended during exacerbation of gastric and duodenal ulcers, and intestinal atony.
Dosage and Administration:
Orally, if necessary after crushing the tablets, with water, one hour before meals and intake of other medications.
For intestinal dysbiosis:
- Adults and children over 12 years: 2-3 tablets, 3 times a day,
- Children from 8 to 12 years: 1-2 tablets, 3 times a day,
- Children from 3 to 7 years: 1 tablet, 3 times a day,
- Children from 1 to 3 years: ½ tablet, 3 times a day.
For bacterial vaginosis (vaginal dysbiosis):
2 tablets, 3 times a day.
The average duration of treatment is 2-3 weeks.
Long-term use and repeated courses of treatment should be carried out only on the recommendation of a doctor.
Side Effects
Allergic reactions to the drug components are possible; rarely - flatulence, diarrhea.
Overdose:
Symptoms: constipation, abdominal pain. Treatment: discontinue the drug.
Drug Interactions
The therapeutic effect of some other orally administered drugs taken concurrently may be reduced.
Special Instructions
The drug can be used in combination therapy with other medications, provided the rule of separate administration is observed (at least 1 hour apart).
Packaging
Tablets.
10 or 15 tablets in a blister pack made of polyvinyl chloride film and printed lacquered aluminum foil. 30 or 60 tablets in a plastic bottle with a screw cap or a polymer jar with a screw cap.
1, 2, 3, or 6 blister packs of 10 tablets, 2 or 4 blister packs of 15 tablets, or 1 bottle or 1 jar, together with the instructions for use, are placed in a cardboard carton.
Storage Conditions
Store in a dry place, protected from light, at a temperature not exceeding 30°C. Keep out of reach of children.
Pharmacy Supply Terms:
Over-the-counter.
Name and Address of the Legal Entity in whose name the Marketing Authorization is issued / Organization handling complaints:
JSC "AVVA RUS", Russia,
121614, Moscow, ul. Krylatskie Kholmy, 30, building 9.
Tel/Fax: +7 (495) 956-75-54
avva.com.ru
Manufacturer:
JSC "AVVA RUS", Russia,
610044, Kirov region, Kirov, ul. Luganskaya, 53a.
Tel.: +7 (8332) 25-12-29, +7 (495) 956-75-54
